Tearsheet
Investment Highlights Market Valuation Price Chart Business Description Interactive Breakdown Better Bets vs. MEIP Latest Trefis Analyses Trade Ideas Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

MEI Pharma (MEIP)

Market Price (9/30/2025): $2.53 | Market Cap: $16.9 Mil
Sector: Health Care | Industry: Biotechnology

MEI Pharma (MEIP)

Market Price (9/30/2025): $2.53
Market Cap: $16.9 Mil
Sector: Health Care
Industry: Biotechnology

Investment Highlights

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -100%		  Very low revenue
Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
1   Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -23 Mil
2   Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is null, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -8.8%
3   Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -159%
0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -100%
1 Very low revenue
Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
2 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -23 Mil
3 Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is null, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -8.8%
4 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -159%

Market Valuation

 9/30/252024202320222021
Share Price CYE$2.53$2.46$5.80$3.78$41.48
Market Cap CYE ($ Mil)16.916.438.625.2262.8
Total Debt ($ Mil)0.00.012.79.68.3
Total Cash ($ Mil)20.538.3100.7153.3153.4
Enterprise Value ($ Mil)-3.616.451.334.8271.1
Valuation Ratios     
P/S TTM0.00.20.80.88.6
P/EBIT TTM-0.70.6-1.1-0.4-5.0
P/E TTM-0.50.9-1.2-0.6-7.3
Sector Ratios     
P/S TTM (Sector)3.73.64.04.57.3
P/EBIT TTM (Sector)-1.6-1.3-1.4-1.3-2.8
P/E TTM (Sector)-1.9-1.5-1.5-1.3-2.8
 9/30/2520242023
Share Price CYE$2.53$2.46$5.80
Market Cap CYE ($ Mil)16.916.438.6
Total Debt ($ Mil)0.00.012.7
Total Cash ($ Mil)20.538.3100.7
Enterprise Value ($ Mil)-3.616.451.3
Valuation Ratios   
P/S TTM0.00.20.8
P/EBIT TTM-0.70.6-1.1
P/E TTM-0.50.9-1.2
Sector Ratios   
P/S TTM (Sector)3.73.64.0
P/EBIT TTM (Sector)-1.6-1.3-1.4
P/E TTM (Sector)-1.9-1.5-1.5

Business Description

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. Show more

Price Returns Compared

Expand for Detailed View

 202020212022202320242025Total [1]
Returns
MEIP Return6%1%-91%53%-58%3%-93%
Peers Return1%8%-9%4%-11%12%2%
S&P 500 Return16%27%-19%24%23%13%106%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: ACT, ALKS, PRGO, LIVN, PCRX. See MEIP Returns vs. Peers.
[3] 2025 data is for the year up to 9/29/2025 (YTD)

Better Bets than MEI Pharma (MEIP)

 MEIPBetter Performance than MEIP
MetricValueIndustry (Biotechnology)
Rev Chg LTM-100.0%ABBV (6.1%), AMGN (12.9%), GILD (3.8%), VRTX (10.5%), REGN (5.4%)
Rev Chg 3Y Avg-8.8%ABBV (0.6%), AMGN (10.0%), GILD (1.6%), VRTX (11.0%), REGN (0.3%)
Total Yield-154.8%ABBV (3.8%), AMGN (7.9%), GILD (7.3%), VRTX (3.6%), REGN (7.9%)
 MEIPBetter Performance than MEIP
MetricValueAll Other Sectors
Rev Chg LTM-100.0%NVDA (71.6%), MSFT (14.9%), AAPL (6.0%), GOOGL (13.1%), AMZN (10.9%)
Rev Chg 3Y Avg-8.8%NVDA (92.0%), MSFT (12.5%), AAPL (1.8%), GOOGL (10.2%), AMZN (11.3%)
Total Yield-154.8%NVDA (2.0%), MSFT (3.3%), AAPL (3.0%), GOOGL (4.2%), AMZN (3.0%)

Latest Trefis Analyses

Trade Ideas

Select past trade ideas related to MEIP and Biotechnology.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
LNTH_8312025_Dip_Buyer_High_CFO_Margins_ExInd_DE08312025LNTHLantheusDip BuyDB | CFO/Rev | Low D/EDip Buy with High Cash Flow Margins
Buying dips for companies with significant cash flows from operations and reasonable debt / market cap		-7.8%-7.8%-8.7%
COO_8312025_Monopoly_xInd_xCD_Getting_Cheaper08312025COOCooper CompaniesMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		0.2%0.2%-4.6%
WST_8312025_Monopoly_xInd_xCD_Getting_Cheaper08312025WSTWest Pharmaceutical ServicesMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		5.9%5.9%-1.3%
BMY_7312025_Dip_Buyer_FCFYield07312025BMYBristol-Myers SquibbDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		1.9%1.9%0.0%
UTHR_7312025_Dip_Buyer_FCFYield07312025UTHRUnited TherapeuticsDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		57.5%57.5%0.0%
Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
LNTH_8312025_Dip_Buyer_High_CFO_Margins_ExInd_DE08312025LNTHLantheusDip BuyDB | CFO/Rev | Low D/EDip Buy with High Cash Flow Margins
Buying dips for companies with significant cash flows from operations and reasonable debt / market cap		-7.8%-7.8%-8.7%
COO_8312025_Monopoly_xInd_xCD_Getting_Cheaper08312025COOCooper CompaniesMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		0.2%0.2%-4.6%
WST_8312025_Monopoly_xInd_xCD_Getting_Cheaper08312025WSTWest Pharmaceutical ServicesMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		5.9%5.9%-1.3%
BMY_7312025_Dip_Buyer_FCFYield07312025BMYBristol-Myers SquibbDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		1.9%1.9%0.0%
UTHR_7312025_Dip_Buyer_FCFYield07312025UTHRUnited TherapeuticsDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		57.5%57.5%0.0%

See Trefis Trade Ideas for more.

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1FTELFitell1068.4%-96.0%
2WOLFWolfspeed886.6%231.8%
3WHLRWheeler Real Estate Investment Trust404.4%-99.7%
4MNDRMobile-health Network Solutions388.0%-71.1%
5QUREuniQure329.5%236.4%
6NUAINew Era Energy & Digital311.7% 
7BQBoqii208.5%153.9%
8DVLTDatavault AI180.5% 
9DFLIDragonfly Energy132.9%-76.4%
10SHFSSHF130.9%-18.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1WOKWORK Medical Technology-91.5%-98.5%
2KALAKala Bio-89.0%-70.5%
3MLTXMoonLake Immunotherapeutics-88.6%-88.5%
4SDMSmart Digital-87.5%-83.8%
5NRIMNorthrim BanCorp-76.1%14.0%
6IOBTIO Biotech-75.5%-60.3%
7ZYBTZhengye Biotechnology-74.9% 
8AMBIAmbipar Emergency Response-74.0%-78.8%
9FGLFounder-63.8%-64.3%
10BINIBollinger Innovations-63.6%-100.0%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1PMIPicard Medical13709.5%13709.5%
2TNFATNF Pharmaceuticals7529.9%-95.9%
3QMMMQMMM2749.6%9228.1%
4WOLFWolfspeed1757.1%231.8%
5EAFGrafTech International1199.0%-24.2%
6SEGGLottery.com646.7%-7.9%
7SLNHSoluna435.8%20.0%
8PTNMPitanium433.3% 
9NUAINew Era Energy & Digital395.6% 
10BREABrera380.3%3593.8%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1BINIBollinger Innovations-96.1%-100.0%
2WOKWORK Medical Technology-90.8%-98.5%
3CJETChijet Motor-90.3%-92.7%
4MLTXMoonLake Immunotherapeutics-88.6%-88.5%
5YAASYouxin Technology-85.8%-98.9%
6ATYRaTyr Pharma-85.1%-78.0%
7CURXCuranex Pharmaceuticals-84.9%28.8%
8YYGHYY-84.6%-80.3%
9NEONNeonode-84.6%-58.7%
10SDMSmart Digital-82.5%-83.8%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1FTELFitell1068.4%-96.0%
2WOLFWolfspeed886.6%231.8%
3WHLRWheeler Real Estate Investment Trust404.4%-99.7%
4MNDRMobile-health Network Solutions388.0%-71.1%
5QUREuniQure329.5%236.4%
6NUAINew Era Energy & Digital311.7% 
7BQBoqii208.5%153.9%
8DVLTDatavault AI180.5% 
9DFLIDragonfly Energy132.9%-76.4%
10SHFSSHF130.9%-18.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1WOKWORK Medical Technology-91.5%-98.5%
2KALAKala Bio-89.0%-70.5%
3MLTXMoonLake Immunotherapeutics-88.6%-88.5%
4SDMSmart Digital-87.5%-83.8%
5NRIMNorthrim BanCorp-76.1%14.0%
6IOBTIO Biotech-75.5%-60.3%
7ZYBTZhengye Biotechnology-74.9% 
8AMBIAmbipar Emergency Response-74.0%-78.8%
9FGLFounder-63.8%-64.3%
10BINIBollinger Innovations-63.6%-100.0%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for MEI Pharma

Financials

MEIPACTALKSPRGOLIVNPCRXMedian
NameMEI Phar.Enact Alkermes Perrigo LivaNova Pacira B. 
Mkt Price-38.7429.0421.7352.3325.3429.04
Mkt Cap0.05.84.83.02.91.22.9
Rev LTM01,2261,5054,3261,3097061,268
Op Inc LTM-23-37441317569175
FCF LTM-36701480257162117209
FCF 3Y Avg-4664132223892143190
CFO LTM-36701521366217135291
CFO 3Y Avg-46641364342133159250

Growth & Margins

MEIPACTALKSPRGOLIVNPCRXMedian
NameMEI Phar.Enact Alkermes Perrigo LivaNova Pacira B. 
Rev Chg LTM-100.0%3.4%-0.2%-2.3%8.2%2.3%1.0%
Rev Chg 3Y Avg-8.8%3.7%9.2%-0.0%8.8%4.8%4.3%
Rev Chg Q-1.9%-2.1%-0.9%10.7%1.7%1.7%
QoQ Delta Rev Chg LTM-0.5%-0.6%-0.2%2.7%0.4%0.4%
Op Mgn LTM--24.9%9.6%13.4%9.7%11.6%
Op Mgn 3Y Avg--22.3%6.2%7.0%11.5%9.3%
QoQ Delta Op Mgn LTM---1.0%0.3%0.7%-3.2%-0.4%
CFO/Rev LTM-57.1%34.6%8.5%16.5%19.1%19.1%
CFO/Rev 3Y Avg-54.5%24.3%7.7%10.7%23.1%23.1%
FCF/Rev LTM-57.1%31.9%5.9%12.4%16.6%16.6%
FCF/Rev 3Y Avg-54.5%21.5%5.3%7.4%20.8%20.8%

Valuation

MEIPACTALKSPRGOLIVNPCRXMedian
NameMEI Phar.Enact Alkermes Perrigo LivaNova Pacira B. 
Mkt Cap0.05.84.83.02.91.22.9
P/S-4.73.20.72.21.62.2
P/EBIT-0.96.411.410.6-23.4-12.62.7
P/E-0.68.613.7-37.4-13.5-9.0-4.8
P/CFO-0.68.39.28.213.28.68.4
Total Yield-154.8%13.7%7.3%-1.4%-7.4%-11.1%-4.4%
Dividend Yield0.0%2.0%0.0%1.3%0.0%0.0%0.0%
FCF Yield 3Y Avg-192.3%13.4%7.1%6.1%3.5%10.5%6.6%
D/E0.00.10.01.20.20.50.1
Net D/E-1.0-0.3-0.21.1-0.00.2-0.1

Returns

MEIPACTALKSPRGOLIVNPCRXMedian
NameMEI Phar.Enact Alkermes Perrigo LivaNova Pacira B. 
1M Rtn-2.9%0.2%-8.5%-7.2%-5.0%-5.0%
3M Rtn-4.9%1.5%-17.7%16.2%6.0%4.9%
6M Rtn-12.8%-12.1%-20.7%33.2%2.0%2.0%
12M Rtn-9.4%5.5%-11.6%-0.4%74.3%5.5%
3Y Rtn-100.7%39.9%-31.8%3.1%-52.4%3.1%
1M Excs Rtn-0.6%-2.1%-11.0%-8.1%-8.1%-8.1%
3M Excs Rtn--2.5%-5.9%-25.0%8.9%-1.3%-2.5%
6M Excs Rtn--5.5%-31.9%-40.1%14.4%-17.6%-17.6%
12M Excs Rtn--6.3%-6.5%-27.6%-15.2%65.8%-6.5%
3Y Excs Rtn-17.1%-38.2%-114.2%-71.2%-130.3%-71.2%

Financials

$ Mil | FY: 6/302025Q32025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q4
Period End3/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/20233/31/202312/31/20229/30/20226/30/2022
Filing Date5/13/20252/12/202511/12/20249/19/20245/9/20242/13/202411/9/20239/26/20235/11/20232/9/202311/14/20229/8/2022
Key Financials Quarterly            
Total Revenue000000651633911
Ebitda-3-3-8-8-10-1255-11-169-18-16
Operating Income-3-3-8-8-10-1255-11-169-18-16
Net Income-3-3-8-18-9-1156-10-1510-17-16
EPS-0.39-0.40-1.20-2.76-1.37-1.668.46-1.51-2.321.54-2.49-2.44
Key Financials TTM            
Total Revenue TTM0006567731054959634241
Ebitda TTM-22-29-3826231637-36-42-47-73-75
Operating Income TTM-23-30-3825221637-37-42-47-74-75
Net Income TTM-32-38-4718262041-32-38-31-54-54
Growth Rates Quarterly            
Total Revenue Growth---100.0%-100.0%-100.0%-100.0%648.0%-87.2%-39.2%176.7%12.5%53.1%
EBITDA Growth71.5%70.9%-114.4%27.6%40.2%-231.3%405.6%31.8%24.1%151.4%9.5%-4.6%
Operating Income Growth71.8%71.1%-115.1%27.1%40.0%-233.7%403.4%31.6%24.0%150.6%9.4%-4.7%
Net Income Growth71.8%75.8%-114.2%-83.5%40.9%-207.9%439.1%37.6%-76.9%184.3%5.1%-91.7%
Margins Quarterly            
EBITDA Margin------84.8%-753.7%-276.5%27.5%-207.6%-141.2%
Operating Income Margin------84.7%-760.5%-278.1%27.3%-208.7%-141.9%
Net Income Margin------86.3%-688.3%-261.9%31.3%-190.4%-140.7%
Cash & Debt            
Total Cash20242738575982101112124138153
Total Debt00001212121313131410
Net Debt / (Cash)-20-24-27-38-45-47-70-88-99-111-125-144
Cash Flows Quarterly            
FCF from Operations-3-4-11-18-3-11-18-11-12-14-15-16
Cash Flows TTM            
FCF from Operations TTM-36-36-43-50-44-53-56-52-57-62-56-49
Returns to Shareholders Quarterly            
Dividends000000000000
Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
Return on Invested Capital (ROIC) Quarterly            
ROIC-2.8%-3.5%-8.5%-8.4%-10.5%-12.8%61.2%-12.9%-19.8%11.2%-24.0%-22.9%
Return on Invested Capital (ROIC) TTM            
ROIC TTM-5.7%-7.5%-9.7%6.6%6.0%4.3%10.2%-10.7%-12.6%-14.8%-24.3%-26.7%

Price Behavior

MEIP Betas & Captures as of 8/31/2025

 1M2M3M6M1Y3Y
Beta3.583.642.320.570.540.57
Up Beta3.97-1.72-2.05-0.040.100.12
Down Beta3.465.062.810.690.631.12
Up Capture273%1299%826%223%116%17%
Bmk +ve Days10223571142415
Stock +ve Days9223360112330
Down Capture439%278%216%82%83%93%
Bmk -ve Days11192754106334
Stock -ve Days12172554115380

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
5/13/20256.2%2.9%8.1%
2/12/20252.3%-0.4%-13.2%
11/14/2024-3.0%-6.6%-14.3%
5/9/2024-1.6%-4.6%-7.2%
2/13/20241.7%-1.9%-15.3%
9/26/2023-1.9%-6.1%-3.7%
5/11/20230.6%7.5%5.6%
2/9/2023-10.3%-2.9%-19.7%
...
SUMMARY STATS   
# Positive643
# Negative578
Median Positive2.0%6.3%8.1%
Median Negative-3.0%-4.6%-13.7%
Max Positive6.2%13.7%35.2%
Max Negative-10.3%-9.3%-29.1%

SEC Filings

Expand for More

Report DateFiling DateFiling
3312025513202510-Q 3/31/2025
12312024212202510-Q 12/31/2024
93020241112202410-Q 9/30/2024
6302024919202410-K 6/30/2024
3312024509202410-Q 3/31/2024
12312023213202410-Q 12/31/2023
93020231109202310-Q 9/30/2023
6302023926202310-K 6/30/2023
3312023511202310-Q 3/31/2023
12312022209202310-Q 12/31/2022
93020221114202210-Q 9/30/2022
6302022908202210-K 6/30/2022
3312022523202210-Q 3/31/2022
12312021210202210-Q 12/31/2021
93020211110202110-Q 9/30/2021
6302021902202110-K 6/30/2021

Insider Activity

Expand for More

 

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.